They didn't see any difference in safety and efficacy for mild to moderate renal impaired patients, which is why they don't exclude them from ph3.
In extension study to 28 weeks and 44 weeks, response rate was 90% for treatment arm, and they used the lowest dose for the maintenance extension period.
AZN bought RDEA for a reason in this case. The drug had stellar result in ph2b.
Market Data 
Markets 
AI
